Skip to Content

Posts tagged with "Drug Development"

  • Drug Development

    Tecfidera’s Price

    Let us take up the case of Tecfidera, the new Biogen/Idec drug for multiple sclerosis, known to us chemists as dimethyl fumarate. It joins the (not very long) list of industrial chemicals (the kind that can be purchased in railroad-car sizes) that are also approved pharmaceuticals for human use. The MS area has seen this… Read More
  • Drug Development

    Sirtuins Live On at GSK

    Well, GSK is shutting down the Sirtris operation in Cambridge, but sirtuins apparently live on. I’m told that the company is advertising for chemists and biologists to come to Pennsylvania to staff the effort, and in this market, they’ll have plenty of takers. We’ll have the sirtuin drug development saga with us for a while… Read More
  • Cancer

    A Therapy Named After You?

    Back last fall I wrote about Prof. Magnus Essand and his oncoloytic virus research. He’s gotten a good amount of press coverage, and has been trying all sorts of approaches to get further work funded. But here’s one that I hadn’t thought of: Essand and his co-workers are willing to name the therapy after anyone… Read More
  • Chemical Biology

    The DNA-Encoded Library Platform Yields A Hit

    I wrote here about DNA-barcoding of huge (massively, crazily huge) combichem libraries, a technology that apparently works, although one can think of a lot of reasons why it shouldn’t. This is something that GlaxoSmithKline bought by acquiring Praecis some years ago, and there are others working in the same space. For outsiders, the question… Read More
  • Academia (vs. Industry)

    The NIH, Pfizer, and Senator Wyden

    Senator Ron Wyden (D-Oregon) seems to be the latest champion of the “NIH discovers drugs and Pharma rips them off” viewpoint. Here’s a post from John LaMattina on Wyden’s recent letter to Francis Collins. The proximate cause of all this seems to be the Pfizer JAK3 inhibitor: Tofacitinib (Xeljanz), approved last November by t… Read More
  • Chemical News

    Automated Med-Chem, At Last?

    I’ve written several times about flow chemistry here, and a new paper in J. Med. Chem. prompts me to return to the subject. This, though, is the next stage in flow chemistry – more like flow med-chem: Here, we report the application of a flow technology platform integrating the key elements of structure–activity relationship (SAR) Read More
  • Biological News

    AstraZeneca Makes a Deal With Moderna. Wait, Who?

    AstraZeneca has announced another 2300 job cuts, this time in sales and administration. That’s not too much of a surprise, as the cuts announced recently in R&D make it clear that the company is determined to get smaller. But their overall R&D strategy is still unclear, other than “We can’t go on like this”, which… Read More
  • Business and Markets

    Affymax In Trouble

    Affymax has had a long history, and it’s rarely been dull. The company was founded in 1988, back in the very earliest flush of the Combichem era, and in its early years it (along with Pharmacopeia) was what people thought of when they thought of that whole approach. Huge compound libraries produced (as much as… Read More
  • Business and Markets

    GlaxoSmithKline’s CEO on the Price of New Drugs

    Well, GlaxoSmithKline CEO Andrew Witty has made things interesting. Here he is at a recent conference in London when the topic of drug pricing came up: . . . Witty said the $1 billion price tag was “one of the great myths of the industry”, since it was an average figure that includes money spent… Read More
  • Drug Development

    Does Baldness Get More Funding Than Malaria?

    OK, let’s fact-check Bill Gates today, shall we? Capitalism means that there is much more research into male baldness than there is into diseases such as malaria, which mostly affect poor people, said Bill Gates, speaking at the Royal Academy of Engineering’s Global Grand Challenges Summit. “Our priorities are tilted by marketplac… Read More